Professor Moein Moghimi
Pioneering the Science and Engineering of Medicines
Scientist · Inventor and Innovator · Academic and Industry Leader
Advancing drug delivery, innate immunity and complement biology, nanoparticle engineering, organ-targeted nanomedicines and engineering biology
Good products are born of good science, and good science takes time, patience, and vision.
Professor Moein Moghimi
Pioneering Science, Enduring Impact
Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine at Newcastle University, Adjoint Professor at the University of Colorado Denver and co-founder and scientific leader of S. M. Discovery Group (SMDG). He is among the world's leading pharmaceutical scientists and a pioneer of nanomedicine, site-specific drug delivery, nanomedicine–immune system interactions, nanosafety and engineering biology. His pioneering discoveries have transformed our understanding of engineered nanoparticle behaviour within the body, establishing definitive principles for designing safer nanomedicines, overcoming biological barriers, preventing infusion-related adverse reactions and targeting therapeutics to specific organs. As a transformative leader, his influence redefines the scientific landscape—propelling breakthrough discoveries, championing institution-building and spearheading therapeutic innovation.
At a Glance: Contributions and Distinctions
Scientist and Researcher
As a global authority in nanomedicine, Professor Moghimi is widely celebrated for his pioneering work in site-specific drug delivery, immune safety of nanopharmaceuticals and engineering biology. His continuous listing among the top 0.1% of world’s most cited scientists by Stanford University/Elsevier reflects his enduring legacy of academic excellence and profound clinical translation impact.
Educator
As an educator, Professor Moghimi has dedicated his career to teaching and nurturing generations of students and scientists, inspiring them to think independently, challenge accepted ideas and pursue advances that strengthen pharmaceutical science and nanomedicine. He is also a highly regarded educational architect who designed contemporary postgraduate curricula that integrated scientific, industrial and business dimensions of nanopharmaceutical development.
Mentor
Professor Moghimi’s sustained guidance has helped shape the careers of numerous students, early-career scientists and clinical fellows, providing the intellectual direction, exacting standards, encouragement and opportunities needed to become independent researchers and professionals and make meaningful contributions to science and society.
Innovator
Professor Moghimi has translated fundamental scientific discoveries into new principles, patented technologies and therapeutic platforms—including organ-targeted drug-delivery systems designed to make medicines safer, more precise and more effective as well as strategies to overcome infusion-related adverse reactions to nanomedicines.
Author and Editor
Through an extensive body of highly cited research papers, reviews, perspectives and book chapters, Professor Moghimi has helped shape scientific thinking across drug delivery, nanomedicine, innate immunity and nanosafety. Prof. Moghimi is an influential voice in scientific literature, serving as Editor-in-Chief of Drug Delivery (Taylor & Francis, USA) and the Journal of Nanotheranostics (Basel), Associate Editor of Molecular Therapy (the flagship journal of The American Society for Gene and Cell Therapy, Cell Press), and an editorial board member of multiple high-impact journals, including Advanced Drug Delivery Reviews, Journal of Controlled Release (Elsevier) and Nanomedicine-UK (Taylor & Francis).
Speaker
As an internationally sought-after speaker, Professor Moghimi has delivered over 400 invited lectures, masterclasses, plenaries and keynotes at the invitation of flagship scientific societies, industry leaders and elite universities.
Founding Director & Principal Advisor
Professor Moghimi was the visionary founder and director of the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at the University of Copenhagen—Denmark’s first interdisciplinary nanomedicine hub—which he established via a competitive, multimillion-euro Danish Research Council award. Complementing this, he has translated discoveries into corporate assets, co-founding S. M. Discovery Group and leading its therapeutic programme. For over three decades, he has provided strategic counsel across industrial, governmental, legal and private sectors. His leadership includes appointments to multiple international grant review boards and serving as a data monitoring committee expert for US corporate clinical research.
Latest Publications
Nature is a constant source of inspiration in my research. It teaches us that the most effective solutions are often founded on simplicity, precision and purpose.